Codiak BioSciences, Inc.
We are a development-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases (cancer, neuromuscular disease and infectious diseases) with high unmet medical need. Exosomes are intercellular transfer mechanisms; they have emerged in recent years as a compelling potential drug delivery vehicle.
There have been no approved exosome-based therapeutics to date.
Our lead product candidates are being developed to treat solid tumors. We expect to enter clinical trials in the second half of 2020.
|Address||35 Cambridge Park Drive, Suite 500 Cambridge, MA 02140|
|Phone Number||(617) 949-4100|
|View Prospectus:||Codiak BioSciences, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-80.7 mil (last 12 months)|
|Price range||$14.00 - $16.00|
|Est. $ Volume||$82.5 mil|
|Manager / Joint Managers||Goldman Sachs/ Evercore/ William Blair/ Wedbush Securities|
|Expected To Trade:||10/14/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|